GlaxoSmithKline PLC (NYSE:GSK) issued its quarterly earnings results on Wednesday. The pharmaceutical company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.02, Morningstar.com reports. The business had revenue of $9.36 billion during the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%.

Shares of GlaxoSmithKline PLC (NYSE GSK) traded down 0.24% during trading on Thursday, reaching $40.75. The company had a trading volume of 3,673,080 shares. The company has a market capitalization of $99.55 billion, a PE ratio of 45.58 and a beta of 1.04. The stock’s 50-day moving average price is $42.93 and its 200-day moving average price is $41.77. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $45.58.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a dividend of $0.491 per share. The ex-dividend date is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 4.82%. GlaxoSmithKline PLC’s dividend payout ratio is presently 233.74%.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/27/glaxosmithkline-plc-nysegsk-announces-earnings-results.html.

A number of analysts have commented on the company. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, May 31st. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday. Finally, BNP Paribas upgraded GlaxoSmithKline PLC from an “underperform” rating to a “neutral” rating and reduced their price target for the stock from $45.58 to $37.20 in a research report on Wednesday, April 5th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have issued a buy rating to the company’s stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and an average target price of $46.00.

Large investors have recently bought and sold shares of the company. Carroll Financial Associates Inc. increased its position in shares of GlaxoSmithKline PLC by 3.8% in the first quarter. Carroll Financial Associates Inc. now owns 8,655 shares of the pharmaceutical company’s stock worth $364,000 after buying an additional 318 shares during the last quarter. Koshinski Asset Management Inc. increased its position in shares of GlaxoSmithKline PLC by 5.6% in the first quarter. Koshinski Asset Management Inc. now owns 10,011 shares of the pharmaceutical company’s stock worth $422,000 after buying an additional 527 shares during the last quarter. GW&K Investment Management LLC increased its position in shares of GlaxoSmithKline PLC by 17.8% in the first quarter. GW&K Investment Management LLC now owns 1,017,202 shares of the pharmaceutical company’s stock worth $42,885,000 after buying an additional 153,555 shares during the last quarter. Dynamic Advisors Solutions LLC increased its position in shares of GlaxoSmithKline PLC by 1,411.4% in the first quarter. Dynamic Advisors Solutions LLC now owns 95,292 shares of the pharmaceutical company’s stock worth $4,017,000 after buying an additional 88,987 shares during the last quarter. Finally, Augustine Asset Management Inc. increased its position in shares of GlaxoSmithKline PLC by 23.6% in the first quarter. Augustine Asset Management Inc. now owns 17,585 shares of the pharmaceutical company’s stock worth $741,000 after buying an additional 3,355 shares during the last quarter. Institutional investors own 8.98% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.